Nitroglycerin as a model of migraine: Clinical and preclinical review
Abstract
Highlights • Nitroglycerin (NTG) is a reliable experimental clinical and preclinical approach to study migraine.• It triggers a migraine-like attack in patients that is indistinguishable from the spontaneous migraine.• NTG mediates migraine-like behavioural and neuronal outcomes in rodents; validated by their response to therapeutics.• Limitations: not effective in all patients, large doses required in animal studies, does not predict efficacy of all therapies.• Adaptations/improvements to the model include reducing the dose by combining with models of ‘latent sensitisation’.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.